Merck & Co., Inc. Target of Unusually Large Options Trading (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) saw some unusual options trading activity on Monday. Investors purchased 227,658 call options on the stock. This is an increase of approximately 784% compared to the typical volume of 25,755 call options.

Merck & Co., Inc. Stock Performance

MRK stock traded up $0.89 on Monday, hitting $144.82. The company’s stock had a trading volume of 7,380,852 shares, compared to its average volume of 10,723,884. The stock has a market cap of $357.30 billion, a price-to-earnings ratio of 115.86, a price-to-earnings-growth ratio of 6.26 and a beta of 0.21. The firm has a 50 day moving average of $136.51 and a two-hundred day moving average of $124.41. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same period last year, the firm earned $2.13 EPS. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 272.00%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MRK. Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday. Morgan Stanley raised shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $116.00 to $179.00 in a research note on Thursday, August 20th. Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Finally, Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective on the stock in a research report on Wednesday, August 12th. Seventeen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $151.32.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the transaction, the executive vice president directly owned 31,716 shares of the company’s stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last 90 days. Corporate insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. California State Teachers Retirement System grew its position in shares of Merck & Co., Inc. by 12,537.4% in the second quarter. California State Teachers Retirement System now owns 484,720,247 shares of the company’s stock valued at $62,286,552,000 after purchasing an additional 480,884,635 shares during the period. BlackRock Inc. boosted its stake in Merck & Co., Inc. by 0.5% in the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after buying an additional 1,073,507 shares during the last quarter. Wellington Management Group LLP grew its holdings in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after buying an additional 1,934,312 shares during the period. Geode Capital Management LLC increased its stake in shares of Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock valued at $6,307,572,000 after acquiring an additional 249,110 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $3,997,933,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.